Back to Directory Azizza Davis Email azizza.davis@nih.gov Institution NIH/ NIAID Address 5601 Fishers Ln Room 9E14 Rockville, MD 20852 USA Request an Update Affiliated Studies IMPAACT 2034: Phase I Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling IMPAACT 2039: Phase I/II Study of the Safety, Immunogenicity, and Efficacy of HIVconsvX Vaccines and Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number TBD Research Area Cure and Immunotherapy Study Status In Development IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age DAIDS Number 38530 Research Area Cure and Immunotherapy Study Status Closed to Follow Up
IMPAACT 2034: Phase I Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling
IMPAACT 2039: Phase I/II Study of the Safety, Immunogenicity, and Efficacy of HIVconsvX Vaccines and Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number TBD Research Area Cure and Immunotherapy Study Status In Development
IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age DAIDS Number 38530 Research Area Cure and Immunotherapy Study Status Closed to Follow Up